Application of Ackermania muciniphila YG2645 in improvement of glycolipid metabolism

The regulation of glycolipid metabolism by Akkermansia muciniphila YG2645 has solved the problem of glycolipid metabolism disorder, achieved the effect of reducing blood sugar and blood lipids, reducing fat and liver weight, and has significant clinical application value.

CN119055686APending Publication Date: 2024-12-03BEIJING YUJING PHARM CO LTD
View PDF 0 Cites 6 Cited by

Patent Information

Application Number
CN202411379321.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate and improve glycolipid metabolism disorders, resulting in the occurrence of metabolic diseases such as obesity and diabetes.

Method used

Using Akkermansia muciniphila YG2645 or its derivative, the host's glycolipids are optimized by inhibiting lipid accumulation, stimulating GLP-1 secretion, regulating intestinal flora and bile acid and taurine metabolism. Metabolic pathway.

Benefits of technology

It significantly reduces blood sugar and blood lipid levels, reduces fat tissue and liver weight, improves sugar tolerance, and has good clinical application prospects and value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005069606060000011
    Figure HDA0005069606060000011
  • Figure HDA0005069606060000012
    Figure HDA0005069606060000012
  • Figure HDA0005069606060000021
    Figure HDA0005069606060000021
Patent Text Reader

Abstract

The invention relates to application of Akkermansia muciniphila YG2645 or a derivative of the Akkermansia muciniphila YG2645 or a composition containing the Akkermansia muciniphila YG2645 to preparation of a product for improving glycolipid metabolism disorder or treating diseases or symptoms related to the glycolipid metabolism disorder. The Ackermansiella muciniphila can effectively inhibit lipid accumulation, promote GLP-1 secretion, regulate intestinal flora and regulate cholic acid, taurine and phospholipid metabolism, so that the Ackermansiella muciniphila has potential treatment potential in the aspects of regulating glycolipid metabolism disorder and treating diseases or symptoms related to the glycolipid metabolism disorder, and has better clinical application prospect and value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, and in particular to the use of Akkermansia muciniphila YG2645 or its derivatives or a composition comprising the foregoing in the preparation of a medicament for improving glucose and lipid metabolism disorders or treating diseases or conditions related to glucose and lipid metabolism disorders. Background Art

[0002] The intestinal microbiome plays a vital role in regulating host lipid metabolism, and its imbalance is closely related to the development of metabolic diseases such as obesity and diabetes.

[0003] Akkermansia muciniphila is a Gram-negative bacterium that mainly exists in the human intestine. It plays a key role in human intestinal health, especially in the maintenance of the mucus layer and the regulation of the immune system. It has the unique ability to degrade mucin in the intestinal mucus layer. More and more studies have confirmed that Akkermansia muciniphila can improve the metabolic health of the host by regulating intestinal barrier function and immune response, and its potential is receiving widespread attention from the scientific community. Summary of the invention

[0004] Purpose of the Invention

[0005] The purpose of the present invention is to use Akkermansia muciniphila YG2645 or its derivatives or a composition containing the foregoing in the preparation of a glucose and lipid metabolism regulator, in the preparation of a drug for promoting GLP-1 secretion, in the preparation of a drug for fat burning and weight loss, and in the preparation of a drug for improving glucose and lipid metabolism disorders or treating diseases or conditions related to glucose and lipid metabolism disorders.

[0006] Solution

[0007] In order to achieve the above object, the present invention provides the following technical solutions.

[0008] The Akkermansia muciniphila YG2645 involved in the following technical scheme was isolated from a stool sample of a healthy child and was identified as Akkermansia muciniphila by 16S rRNA sequencing.

[0009] The 16S rRNA gene sequence of Akkermansia muciniphila YG2645 is shown in SEQ ID NO:1.

[0010] The colony characteristics of the strain include: after culturing on BHI agar medium for 24 to 48 hours, the diameter is between 0.01 mm and 1.0 mm, the colony edge is smooth, milky white, and viscous.

[0011] The Akkermansia muciniphila YG2645 has been deposited in the General Microbiology Center of the China Culture Collection Administration. The address of the depository is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The deposit date is May 10, 2024, and the deposit number is CGMCC No. 30598.

[0012] The inventors of the present invention unexpectedly found that the Akkermansia muciniphila YG2645 has the effects of inhibiting lipid accumulation, stimulating GLP-1 secretion, regulating intestinal flora, regulating bile acid, taurine and glycolipid metabolism, and has obvious advantages over other strains of the same species in these effects. In view of this, the inventors further explored the therapeutic uses related to the above effects, thereby obtaining the following technical solution.

[0013] In a first aspect, the present invention provides use of Akkermansia muciniphila YG2645 or a derivative thereof or a composition comprising the foregoing in the preparation of a glucose and lipid metabolism regulator.

[0014] In a second aspect, the present invention provides the use of Akkermansia muciniphila YG2645 or its derivatives or a composition comprising the foregoing in the preparation of a product that promotes GLP-1 secretion.

[0015] In a possible embodiment, the product is a pharmaceutical product.

[0016] In a third aspect, the present invention provides the use of Akkermansia muciniphila YG2645 or its derivatives or compositions comprising the foregoing in the preparation of fat-burning and weight-loss products.

[0017] In a possible embodiment, the product is a pharmaceutical product.

[0018] In a fourth aspect, the present invention provides the use of Akkermansia muciniphila YG2645 or its derivatives or a composition comprising the foregoing in the preparation of a product for improving lipid metabolism disorders or treating lipid metabolism disorder-related diseases or conditions.

[0019] In a possible embodiment, the product is a pharmaceutical product.

[0020] Optionally, the lipid metabolism disorder-related disease or condition is selected from: hyperglycemia, diabetes, hyperlipidemia, obesity, liver damage, metabolic syndrome, atherosclerosis, cardiovascular disease, cerebrovascular disease, and insulin resistance caused by lipid metabolism disorder.

[0021] Preferably, the method for improving glucose and lipid metabolism disorder or treating glucose and lipid metabolism disorder-related diseases or conditions includes:

[0022] (1) Lower blood sugar levels;

[0023] (2) Improve glucose tolerance;

[0024] (3) Reduce blood lipid levels;

[0025] (4) reduce adipose tissue weight;

[0026] (5) Reduced liver weight;

[0027] (6) Reduce weight.

[0028] Preferably, the improvement of glucose and lipid metabolism disorder or the treatment of glucose and lipid metabolism disorder-related diseases or conditions is achieved by a mechanism selected from the following:

[0029] (1) Inhibit lipid accumulation;

[0030] (2) Stimulate GLP-1 secretion;

[0031] (3) Regulate intestinal flora;

[0032] (4) Regulate bile acid, taurine and glycolipid metabolism.

[0033] The inventors found that the Akkermansia muciniphila YG2645 has excellent properties of inhibiting lipid accumulation and activating GLP-1 secretion; it can accurately regulate the intestinal microbiome, promote the growth of beneficial bacteria, and inhibit the reproduction of harmful microorganisms; it can target and regulate bile acid, taurine and phospholipid metabolism. In the above manner, the Akkermansia muciniphila YG2645 can optimize the host's glycolipid metabolism pathway (including promoting fat thermogenesis, increasing GLP-1 and PYY gene expression, effectively improving host metabolic health, etc.), thereby improving the host's overall glycolipid metabolism level.

[0034] In the above application, the derivative of Akkermansia muciniphila YG2645 is preferably an inactivated bacterial cell, extract, culture, culture supernatant, fermentation product, fermentation supernatant or a combination thereof.

[0035] In the above applications, the drug is preferably formulated for nasal, oral or intra-digestive administration.

[0036] Further preferably, the drug is in the form of pills, tablets, lozenges, lyophilized powders, granules, capsules, aqueous solutions, alcoholic solutions, oily solutions, syrups, emulsions, suspensions, suppositories, solutions for injection or infusion, ointments, gels, tinctures, creams, patches, lotions, sprays, aerosols, powder sprays, effervescent tablets, transdermal therapeutic systems, microcapsules, implants or sticks.

[0037] In a fifth aspect, the present invention provides a method for improving glucose and lipid metabolism disorders, comprising: administering an effective amount of Akkermansia muciniphila YG2645 or a derivative thereof or a composition comprising the foregoing to a subject in need thereof.

[0038] In a sixth aspect, the present invention provides a method for promoting GLP-1 secretion, comprising administering an effective amount of Akkermansia muciniphila YG2645 or a derivative thereof, or a composition comprising the foregoing.

[0039] In a seventh aspect, the present invention provides a method for reducing fat and weight, comprising administering an effective amount of Akkermansia muciniphila YG2645 or a derivative thereof, or a composition comprising the foregoing to a subject in need thereof.

[0040] In an eighth aspect, the present invention provides a method for treating a disease or condition related to lipid metabolism disorder, comprising administering an effective amount of Akkermansia muciniphila YG2645 or a derivative thereof or a composition comprising the foregoing to a subject in need thereof.

[0041] Optionally, the lipid metabolism disorder-related disease or condition is selected from: hyperglycemia, diabetes, hyperlipidemia, obesity, liver damage, metabolic syndrome, atherosclerosis, cardiovascular disease, cerebrovascular disease, and insulin resistance caused by lipid metabolism disorder.

[0042] Preferably, the method for improving glucose and lipid metabolism disorder or treating glucose and lipid metabolism disorder-related diseases or conditions includes:

[0043] (1) Lower blood sugar levels;

[0044] (2) Improve glucose tolerance;

[0045] (3) Reduce blood lipid levels;

[0046] (4) reduce adipose tissue weight;

[0047] (5) Reduced liver weight;

[0048] (6) Reduce weight.

[0049] Preferably, the improvement of glucose and lipid metabolism disorder or the treatment of glucose and lipid metabolism disorder-related diseases or conditions is achieved by a mechanism selected from the following:

[0050] (1) Inhibit lipid accumulation;

[0051] (2) Stimulate GLP-1 secretion;

[0052] (3) Regulate intestinal flora;

[0053] (4) Regulate bile acid, taurine and glycolipid metabolism.

[0054] The "effective amount" may vary depending on the subject, subject organ, symptoms, method of administration, etc., and may be determined based on the judgment of professionals such as doctors, taking into account the type of dosage form, method of administration, age and weight of the patient, symptoms of the patient, etc.

[0055] Beneficial Effects

[0056] The Akkermansia muciniphila YG2645 in the present invention is an Akkermansia muciniphila strain isolated for the first time by the inventors and obtained through performance screening. The inventors found through performance and efficacy studies that the strain has obvious advantages over the standard strain of Akkermansia muciniphila and other Akkermansia muciniphila strains screened during the same period in inhibiting lipid accumulation, promoting GLP-1 secretion, regulating intestinal flora, and regulating bile acid, taurine and phospholipid metabolism. Therefore, the inventors developed its use in regulating glucose and lipid metabolism disorders and treating diseases or conditions related to glucose and lipid metabolism disorders, and it has good clinical application prospects and value. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.

[0058] Figure 1 The inhibitory activity of Akk strains on lipid accumulation in HepG2 cells is shown, as detected in Example 2; wherein the abscissa shows the specific Akk strains and the ordinate shows the triglyceride content; *p<0.05, **p<0.01, ****p<0.0001.

[0059] Figure 2 The effect of Akk strain on GLP-1 expression in SCT-1 cells is shown, as detected in Example 3; wherein the abscissa shows the specific Akk strain and the ordinate shows the relative expression fold change of GLP-1; *p<0.05, ****p<0.0001.

[0060] FIG3 shows the effect of strain YG2645 on HFD-induced obesity in mice, as tested in Example 4; wherein, Figure 3A is the weight change curve of mice. Figure 3B These are pictures of the body shape, liver and adipose tissue of mice at 8 weeks. Figure 3C The adipose tissue and liver weights of mice at week 8 are shown; “*”: p<0.05 compared with the model control group (i.e., HFD) in the YG2645 group; “**”: p<0.01 compared with the model control group in the YG2645 group; “#”: p<0.05 compared with the blank control group (i.e., ND); “##”: p<0.01 compared with the model control group.

[0061] FIG4 shows the effect of the YG2645 strain on HFD-induced glucose metabolism disorders, wherein: Figure 4AThis is the curve of blood glucose level changes in mice during the glucose tolerance test. Figure 4B The results of AUC test of serum glucose in mice. Figure 4C Relative expression levels of several glucose metabolism genes in mouse ileum; “*”: compared with the model control group (i.e., HFD), YG2645 group, p<0.05; “**”: compared with the model control group, YG2645 group, p<0.01; “#”: compared with the blank control group (i.e., ND), p<0.05; “##”: compared with the model control group, p<0.01.

[0062] FIG5 shows the effect of strain YG2645 on HFD-induced lipid metabolism disorders, wherein: Figure 5A Shows the pathological sections of mouse iWAT HE staining (20×, scale bar = 50 μm). Figure 5B The relative diameter measurement results of mouse iWAT adipocytes are shown. Figure 5C The relative expression levels of lipid metabolism genes and inflammatory genes in mouse iWAT are measured. Figure 5D The relative expression levels of lipid metabolism genes and inflammatory genes in mouse eWAT were measured; “*”: compared with the model control group (i.e., HFD), the YG2645 group had p<0.05; “**”: compared with the model control group, the YG2645 group had p<0.01; “#”: compared with the blank control group (i.e., ND), the model control group had p<0.05; “##”: compared with the blank control group, the model control group had p<0.01.

[0063] FIG6 shows the effect of YG2645 strain on HFD-induced lipid metabolism disorders; wherein, Fig. 6A Shown are mouse BAT HE-stained pathological sections (20×, scale bar = 50 μm); Figure 6B Shows the relative diameter measurement results of mouse BAT adipocytes; Figure 6C This is a pathological section of mouse liver stained with HE (20×, scale bar = 50 μm), blue arrow: inflammatory infiltration, yellow arrow: fat vacuoles; Fig.6D Show mouse liver pathological scores; "*": compared with the model control group (i.e., HFD), p<0.05 in the YG2645 group; "**": compared with the model control group, p<0.01 in the YG2645 group; "***": compared with the model control group, p<0.001 in the YG2645 group; "#": compared with the blank control group (i.e., ND), p<0.05; "##": compared with the blank control group, p<0.01 in the model control group, "###": compared with the blank control group, p<0.001 in the model control group.

[0064] Figure 7 shows the regulatory effect of YG2645 on intestinal flora; Fig. 7AThe PCA graph analysis of the samples shows the similarities and differences between different samples; Figure 7B Chaos index analysis reflects species richness; Figure 7C It is Shannon index analysis, reflecting species diversity; Fig.7D This is a phylum-level bacterial community analysis, showing the relative abundance of bacteria in different phyla; Fig. 7E The bacterial community analysis at the genus level shows the relative abundance of bacteria in different genera.

[0065] Figure 8 shows that YG2645 alleviates glucose and lipid metabolism through metabolites; Fig. 8A Beta diversity analysis of the metabolic profile of colonic contents; Figure 8B Volcano plot of differential metabolites generated for the comparison between HFD and ND groups; Figure 8C Volcano plot of differential metabolites generated for the comparison between YG2645 and HFD groups; Fig.8D Comparison results between YG2645 and HFD groups were analyzed for KEGG enrichment to identify affected metabolic pathways; Fig. 8E It is the differential analysis of typical differential metabolites; Fig.8F This is the heat map correlation analysis of typical differential metabolites and intestinal flora; Figure 8G Network diagram analysis of metabolites, biomarkers and intestinal flora; error bars represent SD; *p<0.05, **p<0.01, ***p<0.001.

[0066] The Akkermansia muciniphila YG2645 of the present invention is classified and named as Akkermansia muciniphila, with a preservation date of May 10, 2024; the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration (referred to as CGMCC, address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code 100101); the preservation number is CGMCC No. 30598. DETAILED DESCRIPTION

[0067] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Unless otherwise expressly stated, throughout the specification and claims, the term "including" or its variations such as "comprising" or "including" will be understood to include the stated elements or components, without excluding other elements or other components.

[0068] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.

[0069] In the following examples, unless otherwise specified, other reagents or raw materials used are commercially available.

[0070] Example 1: Isolation and identification of Akkermansia muciniphila

[0071] (1) Strain isolation

[0072] Feces of healthy children in China were collected, and 1 g of fecal specimens were collected. Fecal genomic DNA was extracted using a fecal genome extraction kit (Qiagen, Germany) according to the operating manual, and its concentration and purity were detected using an enzyme reader. The fecal DNA concentration was adjusted to 10 ng / μL as a qPCR template for detection, and samples with positive test results were isolated for strains.

[0073] Take 1g of positive stool sample and put it into 9mL of PBS buffer. Vortex and mix well. Then dilute it tenfold with sterile saline. -4 , 10 -5 , 10 -6 Three dilution gradients were prepared. 0.5 mL of each dilution was added to a 4.5 mL enrichment tube containing mucin culture medium. The mixture was cultured anaerobically at 37 °C for 72 h. PBS was used for continuous gradient dilution. The dilution was 10 -3 ~10 -6 The diluted liquids were spread on BHI agar medium respectively, and 2 plates were spread for each dilution. The solid plates were cultured in an anaerobic incubator at 37°C for 48 to 72 hours. The colonies were picked and purified on BHI agar medium for more than 3 times until the colonies on the plates were consistent in morphology.

[0074] (2) Strain identification

[0075] A. Colony morphology

[0076] After culturing the 6 isolated strains on BHI agar medium for 24 to 48 hours, the diameters of the colonies were between 0.01 and 1.0 mm, and the edges of the colonies were smooth, milky white, and viscous.

[0077] B. 16S rRNA sequencing

[0078] The isolated strains were sent to Sangon Biotech (Shanghai) Co., Ltd. for 16S rRNA gene sequencing, and the 16S rRNA sequencing results were compared with the NCBI database by BLAST (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). Combined with their colony morphological characteristics, the six isolated strains were preliminarily determined to be Akkermansia muciniphila (hereinafter referred to as Akk), and were named YG2603, YG2604, YG2607, YG2609, YG2638 and YG2645, respectively (hereinafter and in the accompanying drawings, they can be used interchangeably with YGMCC2603, YGMCC2604, YGMCC2607, YGMCC2609, YGMCC2638 and YGMCC2645, respectively).

[0079] Through the efficacy screening of the following examples, it was identified that YG2645 has obvious advantages over other strains of the same species in inhibiting lipid accumulation, promoting GLP-1 secretion, regulating intestinal flora, and regulating bile acid, taurine and phospholipid metabolism, namely, Akkermansia muciniphila YG2645 involved in the present invention, and its 16SrRNA sequence is shown in SEQ ID NO: 1.

[0080] Example 2: Detection of the inhibitory activity of Akk strain on lipid accumulation in cells

[0081] In this example, the inhibitory activity of Akk strain on lipid accumulation in HepG2 cells was detected.

[0082] Specifically, triglyceride (TG) assay was used to evaluate the inhibitory effect on lipid accumulation, and the experimental procedure was as follows:

[0083] HepG2 cells (purchased from Wuhan Pronocell Life Science Co., Ltd.) were cultured at 1×10 6The cells were inoculated in a 6-well plate at a density of 10 cells. After reaching 70-80% fusion, the cells were washed with sterile PBS buffer, and then exposed to DMEM medium containing 1mM oleic acid to construct a high-fat model of HepG2 cells; at the same time, normal cultured cells that were not treated with oleic acid were used as a blank control group (i.e., Con group). Three replicate wells were used for each group, and the model group was observed after incubation in DMEM medium containing 1mM oleic acid for 24 hours. Then, the cell culture supernatant was removed, and 2mL of Akk bacterial solution (including the Akk strains isolated and obtained in Example 1 above and the standard strain Akk835 (purchased from the ATCC Biological Standard Resource Center in the United States) was added to each well; the Akk bacterial solution was prepared from fresh antibiotic-free DMEM at a concentration of 10 8 CFU / mL of bacterial solution); at the same time, the group treated with an equal amount of PBS instead of Akk bacterial solution was used as the model control group (i.e., OA group). The formation of intracellular lipid droplets was evaluated using Oil Red O staining, and TG was measured by a TG assay kit (Nanjing Jiancheng Bioengineering Institute, China) to determine the extent of lipid accumulation.

[0084] The results are as follows Figure 1 shown. Figure 1 The results showed that compared with the blank control group, the TG content in the model control group was significantly increased, proving that the model was successfully constructed; and the TG content of the model cells changed differently after being treated with various Akk bacterial solutions. Specifically, although the TG content of the standard strain Akk835 treatment group was lower than that of the model control group, there was no significant difference. The YG2645, YG2638 and YG2609 treatment groups all showed a significant TG content reduction effect, especially the YG2645 group, which had the most significant reduction.

[0085] These results indicate that not all Akk strains have the ability to inhibit lipid accumulation in cells, and that there are significant differences among Akk strains in this regard; for example, Akk835, a standard Akk strain, does not have lipid accumulation inhibitory activity. Among the strains screened by the inventors, YG2645, YG2638, and YG2609 strains have the activity of reducing TG accumulation, especially YG2645, which is the most significant. This indicates that it may have the potential to be a probiotic against obesity.

[0086] Example 3: Detection of the ability of Akk strain to promote cell secretion of GLP-1

[0087] In this example, STC-1 cells were exposed to a live bacterial suspension (10 8 CFU / mL), and the GLP-1 concentration in the supernatant was measured after 3 hours of incubation to detect the ability of Akk strain to promote cell secretion of GLP-1.

[0088] The specific detection methods are as follows:

[0089] Enteroendocrine cells STC-1 (purchased from Shanghai Yaji Biotechnology Co., Ltd.) were cultured at 5×10 5 The cells were inoculated at a density of 10 cells / well in a 12-well plate. After culturing for 24 hours, all STC-1 cell layers were washed with 1 mL / well HEPES buffer, 1.4 mL DMEM was added to each well and incubated for 1 hour. Then 0.1 mL Akk suspension (10 9 CFU / mL, prepared in HEPES buffer), and 10 μL DPP IV (Sigma, DPP4-010) was added. After incubation for 3 hours, the supernatant was collected in a centrifuge tube, centrifuged to remove the bacteria and cells, and the supernatant was collected for detection. The GLP-1 content in the supernatant was detected by enzyme-linked immunosorbent assay (ELISA). The supernatant of STC-1 cells that were not treated with Akk was used as a blank control group (i.e., Con group). The GLP-1 measurement value of each group was normalized and was a relative multiple of the Con group.

[0090] The results are as follows Figure 2 shown. Figure 2 The results showed that compared with the blank control group, Akk835, YGMCC2638 and YGMCC2609 all significantly induced the secretion of GLP-1, and there was no significant difference among the three; however, the YG2645 strain showed the strongest ability to induce GLP-1 secretion, and its effect was significantly stronger than that of other strains.

[0091] Example 4: Detection of the function of Akk strain in regulating glucose and lipid metabolism

[0092] 1. In vivo lipid-lowering experiment

[0093] In this experiment, the effects of Akk strain on glucose and lipid metabolism in mice fed a high-fat diet (HFD) for 8 weeks were investigated.

[0094] 4.1 Animal Experiment Design

[0095] Sixty specific pathogen-free (SPF) 8-week-old C57BL / 6J male mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. The mice were raised under a 12-hour light / 12-hour dark cycle, a temperature of 23±3°C, and a humidity of 50%±10%. All mice were allowed to eat and drink freely, and mouse molar sticks were placed in the breeding environment. They were adaptively raised for 2 days. After being fed with standard feed and 60% high-fat feed for 2 weeks, mice insensitive to high-fat feed were eliminated and divided into 6 groups, 8 mice in each group, distributed in 2 cages, and continued high-fat feed and strain intervention for 6 weeks. The body weight was recorded twice a week, the feed was changed once every two days, and the drinking water was changed once a week.

[0096] The specific groupings are:

[0097] 1) Blank control group (i.e., ND group): standard control feed (Synergy Bio, XTCON50J) + free drinking water, oral administration of 0.1 ml PBS every day for 6 weeks;

[0098] 2) Model control group (i.e., HFD group): 60% high-fat diet (Synergy Biological, XTHF60) + free drinking water, oral administration of 0.1 ml PBS every day for 6 weeks;

[0099] 3) YG2638 group: 60% high-fat diet (Synergy Bio, XTHF60) + free drinking water, intragastric administration of 0.1 ml bacterial solution every day for 6 weeks;

[0100] 4) YG2645 group: 60% high-fat diet (Synergy Biotech, XTHF60) + free drinking water, intragastric administration of 0.1 ml bacterial solution every day for 6 weeks;

[0101] 5) YG2609 group: 60% high-fat diet (Synergy Biotech, XTHF60) + free drinking water, intragastric administration of 0.1 ml bacterial solution every day for 6 weeks;

[0102] 6) AKK835 group: 60% high-fat diet (Synergy Bio, XTHF60) + free drinking water, intragastric administration of 0.1 ml bacterial solution every day for 6 weeks;

[0103] After the modeling was completed, the mice were fasted overnight, and the intraperitoneal glucose tolerance test (IPGTT) was performed. The eyeballs were removed to collect blood, and the collected blood was centrifuged at 4°C, 5000g for 10 minutes to separate the serum and store at -80°C. The liver, ileum, brown fat (BAT), epididymal white fat (eWAT), and inguinal white fat (iWAT) were taken, part of which was fixed with a fixative, and part of which was quickly frozen in liquid nitrogen and stored at -80°C. The contents of the colon and cecum were placed in sterile freeze-drying tubes and quickly frozen in liquid nitrogen and stored at -80°C.

[0104] 4.2 Determination method

[0105] 4.2.1 Pathological Detection

[0106] Fixed BAT, iWAT and liver were embedded in paraffin, sectioned at 5 mm, stained with hematoxylin and eosin (H&E), and the stained slides were observed under an optical microscope.

[0107] 4.2.2 Genetic testing

[0108] iWAT, eWAT, and ileum were taken out at -80℃, and RNA extraction kit (Quanshijin) was used to extract colon tissue RNA, and RNA concentration and purity were determined. TaKaRa kit and manufacturer's instructions were used to reverse transcribe RNA samples. Finally, qPCR kit (Tiangen) and fluorescence quantitative PCR amplification instrument were used. The expression level of each gene was detected.

[0109] 4.3 Experimental Results

[0110] The weight change curve of mice is as follows Figure 3A The body shape, liver and adipose tissue of mice at week 8 are shown in Figure 3B As shown, the fat tissue and liver tumors of mice at 8 weeks Figure 3C shown.

[0111] like Figure 3A As shown, from week 3 to week 8, the body weight of mice fed YG2645 was significantly lower than that of the HFD group, indicating that YG2645 could prevent the development of obesity, and its mechanism may involve limiting the effect of HFD on the body weight of mice and reducing fat mass. Figure 3B-3C The results showed that the body weight and adipose tissue mass of mice in the HFD group increased significantly compared with those in the ND group, indicating the successful construction of the obesity model; however, YG2645 supplementation reduced the HFD-induced body weight gain, liver weight, and fat accumulation (eWAT and iWAT).

[0112] From the above results, it can be seen that the YG2645 strain can effectively prevent the development of obesity and significantly reduce the fat content in the body.

[0113] 2. Intraperitoneal glucose tolerance test and glucose metabolism gene expression level test

[0114] Before the intraperitoneal glucose tolerance test (IPGTT), mice were fasted overnight but not water. Blood samples were collected from the tip of the tail vein to detect baseline (t = 0) blood glucose, and glucose levels were tested 30, 60, 90, and 120 minutes after intraperitoneal injection of 40% (w / v) glucose (2 g / kg body weight). Blood glucose levels were measured using a glucometer (Accu-Check; Roche, Basel, Switzerland), and the relative expression levels of several sugar metabolism genes in the ileum were detected by fluorescent quantitative PCR.

[0115] In the glucose tolerance test, the blood sugar level curve is as follows Figure 4A As shown; the mouse serum glucose AUC test results are as follows Figure 4B As shown in the figure; the relative expression levels of several sugar metabolism genes in mouse ileum (normalized by internal reference genes) are shown in the figure Figure 4C shown.

[0116] like Figure 4A As shown, at each measuring time point (0, 30, 60, 90, and 120 min), the blood glucose level in the HFD group was significantly higher than that in the ND group, while YG2645 treatment significantly improved the glucose clearance rate in HFD-fed mice.

[0117] like Figure 4B As shown, YG2645 treatment significantly reduced serum glucose AUC in HFD-treated mice.

[0118] like Figure 4C As shown, the expression of glucose metabolism genes fgf15, pyy and gcg in the ileum was upregulated, and FGF15 was released into the liver, thereby reducing the expression of key gluconeogenic enzymes through a cascade reaction.

[0119] 3. HE staining, pathological analysis and related gene detection of inguinal white adipose tissue (iWAT)

[0120] Refer to 4.2 for the test method.

[0121] The results are shown in Figure 5.

[0122] Figure 5A The HE staining results of mouse iWAT pathological sections are shown. Figure 5B The relative diameters of mouse iWAT adipocytes are shown; Figure 5A and 5B It can be seen that the size of adipocytes in iWAT tissue of mice treated with YG2645 was significantly reduced compared with that in the HFD group.

[0123] Figure 5C The results of the expression level detection of lipid metabolism genes and inflammatory genes in mouse iWAT are shown. Figure 5D The results of the expression level detection of lipid metabolism genes and inflammatory genes in mouse eWAT are shown; Figure 5C and 5D It can be seen that YG2645 can upregulate the expression of key brown fat genes (such as ucp-1, pgc1α and ppar-α) in iWAT and eWAT, confirming that it can induce beigeization of iWAT and eWAT. In addition, YG2645 also upregulated the relative expression of some anti-inflammatory cytokines (such as il-10, il-4 and foxp3) that were inhibited by HFD, further demonstrating its anti-inflammatory properties.

[0124] 4. HE staining, pathological analysis and related gene detection of brown adipose tissue (BAT)

[0125] Refer to 4.2 for the test method.

[0126] The results are shown in Figure 6.

[0127] As shown in Figure 6, compared with the HFD group, although YG2645 supplementation had no significant effect on BAT weight (see Figure 3C), but reversed the HFD-induced changes in BAT morphology; e.g. Fig. 6A and 6B As shown in the figure, the increase in lipid droplets and whitening of adipocytes in BAT of the HFD group indicated impaired thermogenic function, while YG2645 treatment restored the BAT morphology to normal and reduced lipid accumulation, indicating that YG2645 can prevent HFD-induced BAT dysfunction and enhance thermogenic efficiency. In addition, HFD induced severe hepatic steatosis, manifested by cytoplasmic vacuoles, inflammatory cell infiltration, and significant lipid accumulation in the liver, while YG2645 treatment significantly reduced adipocyte size and inflammatory infiltration in the liver of HFD-fed mice (e.g. Figure 6C and Fig.6D shown).

[0128] Example 5: YG2645 targeted regulation of characteristic intestinal flora in HFD mice

[0129] In this example, 16S rRNA gene sequencing technology was used to analyze the effect of YG2645 on the intestinal flora structure of mice with HFD-induced lipid metabolism disorders.

[0130] like Figure 7B and 7C As shown, compared with the HFD group, YG2645 significantly increased the number of intestinal-specific OTUs and improved the Chao index, indicating that the diversity of intestinal flora was improved. The Shannon index also confirmed the effect of YG2645 on improving the α diversity of intestinal flora. In addition, in order to explore the differences between microbial diversity, we analyzed β diversity by principal coordinate analysis (PCoA) and Bray-Curtis distance. The PCA plot showed that the NC group, HFD group, and YG2645 group presented different clustering patterns, indicating that there were significant differences in the flora structure among the three groups. Specifically, YG2645 significantly changed the β diversity of intestinal flora ( Fig. 7A At the phylum level, YG2645 intervention significantly increased the relative abundance of Actinobacteriota, Verrucomicrobiota, and Bacteroidota, while reduced the relative abundance of Firmicutes and Desulfobacterota compared with the HFD group ( Fig.7D At the genus level, YG2645 significantly increased the abundance of several beneficial bacteria (such as Akkermansia, Blautia, Lactobacillus, and Faecalibacterium), while reducing the abundance of several harmful bacteria (such as Enterococcus, Dubosiella, Desulfovibrio, and Lachnospiraceae_UCG-006) ( Fig. 7E ).

[0131] Example 6: YG2645 improves glucose and lipid metabolism disorders by regulating bile acid and choline metabolism

[0132] To further explore the effect of YG2645 on the fecal metabolome of HFD-induced mice, we analyzed the differences in fecal metabolomes among different groups. Partial least squares discriminant analysis (PLS-DA) is a supervised machine learning algorithm that can distinguish the overall variability of samples.

[0133] The PLS-DA visualization results are shown in Fig. 8A As shown; Fig. 8A The results showed that the NC, HFD, and YG2645 groups showed a clear clustering trend, indicating that YG2645 intervention significantly affected the fecal metabolome of HFD-induced mice.

[0134] The volcano plot of the differential metabolites between the HFD group and the ND group is shown in Figure 8B The volcano plot of differential metabolites generated by the comparison between the YG2645 and HFD groups is shown in Figure 8C shown by Figure 8B and 8C It can be seen that compared with the ND group, 674 metabolites were increased and 187 metabolites were decreased in the HFD group; compared with the HFD group, 128 metabolites were increased and 131 metabolites were decreased in the YG2645 group.

[0135] To understand the metabolic changes in the samples, we performed metabolic pathway enrichment analysis based on differential metabolites. Fig.8D As shown, Fig.8D The results showed that 20 metabolic pathways were significantly enriched in the YG2645 group compared with the HFD group, among which the enrichment of choline metabolism, primary bile acid biosynthesis and secondary bile acid biosynthesis pathways was particularly significant.

[0136] In addition, we screened out 9 differential metabolites from these three significantly enriched metabolic pathways (P < 0.05, VIP > 1), among which the levels of cholic acid, taurine, phospholipids (Lysopc (18:3 (6Z, 9Z, 12Z) / 0:0), Lysopc (15:0 / 0:0)) and Dg (15:0 / 16:0 / 0:0)) in the YG2645 group were increased, while the levels of chenodeoxycholic acid, deoxycholic acid, Pa (8:0 / I-14:0) and 3A,7A,12A-Trihydroxy-5B-Cholestan-26-Al were decreased (see Table 2). Fig. 8E ).

[0137] By analyzing the relationship between changes in intestinal metabolite composition and the abundance of microbial OTUs, we found that at the genus level, the contents of bile acid, taurine, phospholipids (Lysopc(18:3(6Z,9Z,12Z) / 0:0), Lysopc(15:0 / 0:0)), and Dg(15:0 / 16:0 / 0:0) were positively correlated with Akkermansia, Blautia, Lactobacillus, and Faecalibacterium, but negatively correlated with Enterococcus, Dubosiella, Desulfovibrio, and Lachnospiraceae_UCG-006 (see Fig.8F ).

[0138] To explore the mechanism by which YG2645 improves glucose and lipid metabolism in mice, we performed Pearson correlation analysis to analyze the relationship between differential bacterial genera, key metabolites and glucose and lipid metabolism indicators. The results are shown in Figure 8G The results showed that bile acid, taurine, and phospholipids (Lysopc(18:3(6Z,9Z,12Z) / 0:0), Lysopc(15:0 / 0:0)) were positively correlated with Akkermansia, Blautia, Lactobacillus, and Faecalibacterium, negatively correlated with fasting blood glucose, eWAT, iWAT, and liver weight, and positively correlated with GLP-1 and PYY gene expression. Therefore, bile acid, taurine, and phospholipids (Lysopc(18:3(6Z,9Z,12Z) / 0:0), Lysopc(15:0 / 0:0)) may be the key metabolites of YG2645 in alleviating lipid metabolism disorders.

[0139] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of Akkermansia muciniphila YG2645 or its derivatives or compositions comprising the foregoing in the preparation of a glucose and lipid metabolism regulator, wherein: The Akkermansia muciniphila YG2645 is deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration, with a deposit date of May 10, 2024 and a deposit number of CGMCC No.30598.

2. Use of Akkermansia muciniphila YG2645 or its derivatives or compositions comprising the foregoing in the preparation of products that promote GLP-1 secretion, wherein: The Akkermansia muciniphila YG2645 is deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration, with a deposit date of May 10, 2024 and a deposit number of CGMCC No.30598.

3. Use of Akkermansia muciniphila YG2645 or its derivatives or compositions comprising the foregoing in the preparation of fat-burning and weight-loss products, wherein: The Akkermansia muciniphila YG2645 is deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration, with a deposit date of May 10, 2024 and a deposit number of CGMCC No.30598.

4. Use of Akkermansia muciniphila YG2645 or its derivatives or compositions comprising the foregoing in the preparation of products for improving glucose and lipid metabolism disorders or treating diseases or conditions related to glucose and lipid metabolism disorders, wherein: The Akkermansia muciniphila YG2645 is deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration, with a deposit date of May 10, 2024 and a deposit number of CGMCC No.30598.

5. The use according to claim 4, characterized in that: The diseases or conditions related to glucose and lipid metabolism disorders are selected from: hyperglycemia, diabetes, hyperlipidemia, obesity, liver damage, metabolic syndrome, atherosclerosis, cardiovascular disease, cerebrovascular disease, and insulin resistance caused by glucose and lipid metabolism disorders.

6. The use according to claim 4, characterized in that: The improvement of glucose and lipid metabolism disorder or the treatment of glucose and lipid metabolism disorder-related diseases or conditions include: (1) Lower blood sugar levels; (2) Improve glucose tolerance; (3) Reduce blood lipid levels; (4) reduce adipose tissue weight; (5) Reduced liver weight; (6) Reduce weight.

7. The use according to claim 4, characterized in that: The improvement of glucose and lipid metabolism disorder or the treatment of glucose and lipid metabolism disorder-related diseases or conditions is achieved by a mechanism selected from the following: (1) Inhibit lipid accumulation; (2) Stimulate GLP-1 secretion; (3) Regulate intestinal flora; (4) Regulate bile acid, taurine and glycolipid metabolism.

8. The use according to any one of claims 1 to 7, characterized in that: The 16S rRNA gene sequence of Akkermansia muciniphila YG2645 is shown in SEQ ID NO:

1.

9. The use according to any one of claims 1 to 7, characterized in that: The derivative is the inactivated bacteria, extract, culture, culture supernatant, fermentation product, fermentation supernatant or a combination thereof of Akkermansia muciniphila YG2645.

10. The use according to any one of claims 2 to 7, characterized in that: The product described is a pharmaceutical product.

Citation Information

Cited By

  • Ackermania muciniphila YG2604 and application thereof in treatment of constipation

    CN119639617A

  • Ackermania muciniphila Akk21 with hypoglycemic capacity, and application, product and method of ackermania muciniphila Akk21

    CN119662483A

  • Ackermansiella muciniphila for improving obesity and glycolipid metabolism

    CN120555307A

  • Antibody targeted modified double-bacterium-prebiotic delivery system as well as preparation method and application thereof

    CN121421987A

  • Antibody-targeted modified dual-strain prebiotic delivery system, preparation method and application

    CN121421987B